Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition

Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.